Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A monoclonal antibody over monalizumab for the treatment of cancer
Abstract A semimechanistic pharmacokinetic (PK)/receptor occupancy (RO) model was constructed to differentiate a next generation anti‐NKG2A monoclonal antibody (KSQ mAb) from monalizumab, an immune checkpoint inhibitor in multiple clinical trials for the treatment of solid tumors. A three‐compartmen...
Na minha lista:
Main Authors: | , , , , , , , , , , |
---|---|
Formato: | Livro |
Publicado em: |
Wiley,
2021-03-01T00:00:00Z.
|
Assuntos: | |
Acesso em linha: | Connect to this object online. |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Área/Cota: |
A1234.567 |
---|---|
Cód. Barras: 1 | Disponível |